leuprolide / Auritec Pharma - LARVOL DELTA

🚀 Join the conversation on the groundbreaking #EMBARK Phase 3 trial at #ESMO2023! @NealShore shares insights on enzalutamide + leuprolide for high-risk prostate cancer. 📈 Results show promise in extending survival. Watch the video: [video]https://bit.ly/3QxG7Rl #ProstateCancer

P3 data

Enzalutamide With or Without Leuprolide and Leuprolide Alone in Biochemically Recurrent Prostate Cancer (THE ASCO POST) - "In the phase III EMBARK trial reported in The New England Journal of Medicine, Stephen J. Freedland, MD, and colleagues found that enzalutamide/leuprolide and enzalutamide alone improved metastasis-free survival vs leuprolide alone in patients with high-risk biochemical recurrence of prostate cancer."

Online posting

The ACDC-RP Phase II Trial: Understanding the Impact on High-Risk Prostate Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen (Urotoday) - "Zach Klaassen is joined by...to analyze the ACDC-RP Phase II Trial concerning neoadjuvant therapy in high-risk prostate cancer patients. The trial focuses on the combination of cabazitaxel, abiraterone, and leuprolide, examining the high treatment failure rates and mortality in this patient group. The discussion details the trial's design, methodology, endpoints, and safety assessments while emphasizing early treatment intensification."

Video

The PRONOUNCE and HERO Trials: The Cardiovascular Safety of Degarelix, Leuprolide, and Relugolix for Prostate Cancer (VuMedi) - https://www.vumedi.com/video/the-pronounce-and-hero-trials-the-cardiovascular-safety-of-degarelix-leuprolide-and-relugolix-for-pr/

Enzalutamide Plus Leuprolide Improves Metastasis-Free Survival in nmCSPC (Targeted Oncology) - "'If approved, we hope to bring a new option to men earlier in the course of their disease,' Stephen J. Freedland, MD...stated in the press release."

Media quote

Enzalutamide With or Without Leuprolide Offers MFS Benefit Vs Leuprolide Alone in nmHSPC With High-risk BCR (OncLive) - "'The EMBARK study is a phase 3 trial exploring the potential of enzalutamide in patients with nmHSPC with high-risk BCR,' said Stephen J. Freedland, MD...said in the release."

Media quote

XTANDI (enzalutamide) plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide (PRNewswire) - "'There are patients with localized prostate cancer who undergo prostatectomy or radiation therapy in an attempt to cure their disease, but, unfortunately, some patients will develop BCR,' said Neal Shore, M.D...'Importantly, some patients with BCR are at very high risk for developing metastatic disease, which can lead to a cascade of therapeutic interventions. The clinical goal of BCR therapy is to delay cancer progression and avoid metastatic disease. The MFS results from the EMBARK study demonstrate that this intervention with XTANDI plus leuprolide was statistically significant for patients with high-risk BCR.'"

Media quote

Enzalutamide/Leuprolide Extends MFS in nmHSPC With High-Risk Bochemical Recurrence (Targeted Oncology) - "'A robust phase 3 trial to better inform patient physician shared decision making for BCR patients has been an unmet need, specifically for the important endpoint of metastasis free survival,' Neal Shore, MD...told Targeted Oncology....'As EMBARK is a positive trial, the results will assuredly better inform healthcare provider's and patient's regarding treatment choices,' said Shore."

Media quote

The EMBARK Study: A Phase 3 Randomized Study of Enzalutamide Plus Leuprolide and Enzalutamide Monotherapy in High-Risk Nonmetastatic Hormone-Sensitive Prostate Cancer with Rising PSA After Local Therapy - Stephen Freedland (Urotoday) - "The objective of EMBARK was to value the efficacy and safety of enzalutamide in combination with leuprolide acetate or monotherapy compared with leuprolide alone earlier in the disease course and specifically in those with high-risk non-metastatic hormone-sensitive prostate cancer."

Video

Prostate roundup what have we learned from EAU and ASCO 2022? (ecancer) - "Prof Efstathiou mentions the results from the phase 3 HERO study that investigated sustained castration to < 20 ng/dl for relugolix vs. leuprolide in men with advanced prostate cancer from EAU 2022."

Video

Novel Hormonal Therapies in Prostate Cancer - Episode 2: Case 1: A 59-Year-Old Man With Nonmetastatic CRPC (Targeted Oncology) - "Alan Bryce, MD: We're going to move on to case No. 1. I'm going to hand this off to Dr Efstathiou. Eleni Efstathiou, MD, PhD: Thank you very much. Alan and Daniel [Landau], it's great to be with you. Thank you for having me. Let's talk about our patients and the cases we deal with every day....At that point, the decision was made to initiate androgen deprivation, and a depot leuprolide of 45 mg for 6 month dosage was given. The patient transferred his care, and the PSA nadir is unknown at that point."

Video